Literature DB >> 34173663

Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature.

Eric J Chow1, Branden Maust2, Katherine M Kazmier3, Caleb Stokes2.   

Abstract

Remdesivir is an RNA polymerase inhibitor that is commonly used in the treatment of patients with severe acute coronavirus disease 2019 (COVID-19). As the severe acute respiratory syndrome coronavirus 2 spreads, the use of remdesivir is likely to increase. Most of the patients treated with remdesivir will not experience any adverse events although some side effects have been reported. Here, we describe a case of sinus bradycardia associated with remdesivir therapy in a pediatric patient with severe acute COVID-19.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; bradycardia; pediatrics; remdesivir

Mesh:

Substances:

Year:  2021        PMID: 34173663      PMCID: PMC8557381          DOI: 10.1093/jpids/piab029

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   5.235


  7 in total

Review 1.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

2.  Remdesivir for the Treatment of Covid-19 - Final Report.

Authors:  John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane
Journal:  N Engl J Med       Date:  2020-10-08       Impact factor: 91.245

3.  Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.

Authors:  James C Gubitosa; Parul Kakar; Christine Gerula; Hernando Nossa; Diana Finkel; Kristin Wong; Megna Khatri; Hasan Ali
Journal:  JACC Case Rep       Date:  2020-10-28

4.  Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.

Authors:  Maria Isabel Sanchez-Codez; Moises Rodriguez-Gonzalez; Irene Gutierrez-Rosa
Journal:  Eur J Pediatr       Date:  2021-01-23       Impact factor: 3.183

5.  Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.

Authors:  Anthony Touafchia; Haleh Bagheri; Didier Carrié; Geneviève Durrieu; Agnès Sommet; Laurent Chouchana; François Montastruc
Journal:  Clin Microbiol Infect       Date:  2021-02-27       Impact factor: 8.067

6.  Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.

Authors:  Fotios Barkas; Chrysoula-Paraskevi Styla; Aris Bechlioulis; Haralampos Milionis; Evangelos Liberopoulos
Journal:  J Cardiovasc Dev Dis       Date:  2021-02-12
  7 in total
  6 in total

1.  Bradyarrhythmia After Remdesivir Administration in SARS-CoV-2: A Review of Literature and Meta-Analysis of Observational Studies in Epidemiology.

Authors:  Safa Al-Jammali; Rana Al-Zakhari; Nicholas Sheets; Arun Mahtani; Veronika Stefanishina; Nidal Isber
Journal:  Cardiol Res       Date:  2022-05-10

Review 2.  Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children.

Authors:  Eric J Chow; Janet A Englund
Journal:  Infect Dis Clin North Am       Date:  2022-02-01       Impact factor: 5.905

Review 3.  Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review.

Authors:  Maryam Nabati; Homa Parsaee
Journal:  Cardiovasc Toxicol       Date:  2021-10-13       Impact factor: 2.755

Review 4.  Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.

Authors:  Francesco Nappi; Adelaide Iervolino; Sanjeet Singh Avtaar Singh
Journal:  Biomedicines       Date:  2022-02-14

Review 5.  Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children.

Authors:  Alexandra Chera; Antoanela Tanca
Journal:  Discoveries (Craiova)       Date:  2022-06-30

Review 6.  Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.

Authors:  Jialu Huang; Yubo Ding; Jingwei Yao; Minghui Zhang; Yu Zhang; Zhuoyi Xie; Jianhong Zuo
Journal:  Vaccines (Basel)       Date:  2022-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.